Comment

  • 28 November 2018

    Limited uptake likely for Nabriva’s CABP therapy lefamulin

    Nabriva Therapeutics’ intravenous (IV) and per oral (PO) lefamulin for community-acquired bacterial pneumonia (CABP), one of the most common infectious diseases, has experts anticipating limited market uptake for both following a...

  • 27 November 2018

    Orphan drugs in 2017: an analysis of clinical trials

    In 2017, the FDA approved 80 drugs with orphan drug designation. GlobalData’s Pharma Intelligence Center database covers the clinical trials for those 80 drugs, including a key analysis of the...

  • 19 November 2018

    Is the GAIN Act stimulating antibiotic R&D?

    In July 2012, the Generating Antibiotic Incentives Now (GAIN) Act was signed into law by the Obama administration as part of the FDA Safety and Innovation Act. Since then, there...